250 related articles for article (PubMed ID: 33924581)
1. Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy.
Fanetti G; Polesel J; Fratta E; Muraro E; Lupato V; Alfieri S; Gobitti C; Minatel E; Matrone F; Caroli A; Revelant A; Lionello M; Zammattio Polentin V; Ferretti A; Guerrieri R; Chiovati P; Bertolin A; Giacomarra V; Paoli A; Vaccher E; Sartor G; Steffan A; Franchin G
Nutrients; 2021 Apr; 13(4):. PubMed ID: 33924581
[TBL] [Abstract][Full Text] [Related]
2. Objective evaluation of nutritional status using the prognostic nutritional index during and after chemoradiotherapy in Japanese patients with head and neck cancer: a retrospective study.
Fujiwara D; Tsubaki M; Takeda T; Miura M; Nishida S; Sakaguchi K
Eur J Hosp Pharm; 2021 Sep; 28(5):266-270. PubMed ID: 34426479
[TBL] [Abstract][Full Text] [Related]
3. Excellent local control and survival after postoperative or definitive radiation therapy for sarcomas of the head and neck.
Andrä C; Rauch J; Li M; Ganswindt U; Belka C; Saleh-Ebrahimi L; Ballhausen H; Nachbichler SB; Roeder F
Radiat Oncol; 2015 Jul; 10():140. PubMed ID: 26156022
[TBL] [Abstract][Full Text] [Related]
4. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
5. The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy.
Miao J; Xiao W; Wang L; Han F; Wu H; Deng X; Guo X; Zhao C
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1263-1273. PubMed ID: 28247035
[TBL] [Abstract][Full Text] [Related]
6. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.
Daly ME; Lau DH; Farwell DG; Luu Q; Donald PJ; Chen AM
Am J Otolaryngol; 2013; 34(6):631-5. PubMed ID: 23954137
[TBL] [Abstract][Full Text] [Related]
8. Locoregional Control and Toxicity in Head and Neck Carcinoma Patients following Helical Tomotherapy-Delivered Intensity-Modulated Radiation Therapy Compared with 3D-CRT Data.
Santa Cruz O; Tsoutsou P; Castella C; Khanfir K; Anchisi S; Bouayed S; Matzinger O; Ozsahin M
Oncology; 2018; 95(2):61-68. PubMed ID: 29895020
[TBL] [Abstract][Full Text] [Related]
9. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer.
Vlacich G; Stavas MJ; Pendyala P; Chen SC; Shyr Y; Cmelak AJ
Radiat Oncol; 2017 Jan; 12(1):13. PubMed ID: 28086954
[TBL] [Abstract][Full Text] [Related]
10. IMRT-SIB with concurrent and neo-adjuvant platinum-based chemotherapy for locally advanced head and neck squamous cell cancer: analysis of clinical outcomes in a retrospective series of a single institution.
Mazzeo E; Antognoni P; Parmiggiani M; D'Ambrosio C; De Marco G; Marra L; Gottardi G; Bertoni F
Tumori; 2014; 100(6):652-9. PubMed ID: 25688499
[TBL] [Abstract][Full Text] [Related]
11. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
[TBL] [Abstract][Full Text] [Related]
12. [Intensity Modulated Hyperfractionated Accelerated Radiotherapy to Treat Advanced Head and Neck Cancer - Predictive Factors of Overall Survival].
Cvek J; Knybel L; Stránský J; Matoušek P; Res O; Zeleník K; Otáhal B; Molenda L; Skácelíková E; Stieberová N; Čermáková Z; Feltl D
Klin Onkol; 2017; 30(4):282-288. PubMed ID: 28832174
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application Value of the Prognostic Nutritional Index for Predicting Survival in Patients with Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy or Radiotherapy.
Xiao L; Lyu J; Liu X; Li K; Wang Y; Zhang R; Chen T; Li T
Nutr Cancer; 2021; 73(10):1933-1940. PubMed ID: 33044092
[TBL] [Abstract][Full Text] [Related]
14. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
[TBL] [Abstract][Full Text] [Related]
15. Pre-therapeutic nutritional assessment for predicting severe adverse events in patients with head and neck cancer treated by radiotherapy.
Kono T; Sakamoto K; Shinden S; Ogawa K
Clin Nutr; 2017 Dec; 36(6):1681-1685. PubMed ID: 27847115
[TBL] [Abstract][Full Text] [Related]
16. The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin.
Fujiwara Y; Sato Y; Hayashi N; Fukuda N; Wang X; Nakano K; Ohmoto A; Urasaki T; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takahashi S
J Geriatr Oncol; 2023 Jun; 14(5):101523. PubMed ID: 37229881
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
[TBL] [Abstract][Full Text] [Related]
20. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy.
Schoenfeld JD; Sher DJ; Norris CM; Haddad RI; Posner MR; Balboni TA; Tishler RB
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):308-14. PubMed ID: 21075557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
